Bacterial Pathogens News Today

Promising Minimum Inhibitory Concentration (MIC) activity in Phase I/II trial for urinary tract infections (UTI) and urosepsis with an increase in dosage expected to begin in the next several weeksExpansion of Phase I/II trial for diabetic foot infections (DFI) with efficacy achieved and now moving towards the initiation of a Phase III registrational trial in Indonesia scheduled to commence in Q3 2024RECCE® 327 (R327) shown to be effective against more than 300 strains of bacterial pathogen...

In this multicentre randomised controlled trial, Mariana Bichuette Cartuliares and colleagues evaluate point-of-care multiplex polymerase chain reaction in antibiotic treatment of patients acutely admitted with suspected community-acquired pneumonia in Denmark.

Leveraging data from 1715 children in the MAL-ED birth cohort study, Stephanie A Brennhofer and colleagues model the expected reduction in diarrhea episodes, antibiotic use, and bystander pathogen exposure to antibiotics through the administration of Shigella vaccines.

Qrons Announces the Addition of Professor Shiri Navon-Venezia to its ...

Ruchita Balasubramanian and colleagues, estimate the incidence of hospital-associated infections resistant to antibiotics in 195 countries using point prevalence survey data from across the globe.

Kasim Allel and colleagues systematically review published literature from low- and middle-income countries and meta-analyse data extracted from 109 articles to explore the impact of bloodstream infections caused by antibiotic-resistant bacteria.

James Neal Russell and colleagues report a global neonatal sepsis observational cohort study (NeoOBS) exploring patterns of antibiotic use, pathogens and prediction of mortality in hospitalised neonates and young infants with sepsis.

FDA’s Center for Food Safety and Applied Nutrition CFSAN and Office of Food Policy and Response OFPR routinely publish list of possible new topics for guidance documents or revisions to existing guidance documents that will be a priority during the next 12 months.

Five leading pathogens -- Staphylococcus aureus, Escherichia coli, Streptococcus pneumoniae, Klebsiella pneumoniae, and Pseudomonas aeruginosa -- were responsible for 54.9 per cent of deaths among the investigated bacteria.

It may be time to use conventional scaling and an anti-infective drug treatment strategy to treat severe periodontitis, according to a commentary.